Published in PLoS One on January 22, 2013
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev (2014) 1.38
Clinical Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria at the China-Myanmar Border. Am J Trop Med Hyg (2015) 1.05
Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season. Malar J (2015) 0.97
Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine. Malar J (2015) 0.95
In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene. Malar J (2013) 0.88
An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin-Piperaquine Versus Artemether-Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa. Am J Trop Med Hyg (2015) 0.78
Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR. Malar J (2014) 0.75
Budget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania. Pharmacoeconomics (2016) 0.75
Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda. Malar J (2017) 0.75
Comparison of anti-malarial drugs efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis. Malar J (2017) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg (1995) 7.63
Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg (2006) 5.91
Effectiveness of antimalarial drugs. N Engl J Med (2005) 4.83
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis (2010) 3.59
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol (1998) 3.53
Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol (2004) 3.48
Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev (2009) 3.26
Piperaquine: a resurgent antimalarial drug. Drugs (2005) 2.80
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78
Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? Lancet Infect Dis (2009) 2.46
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42
A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med (2011) 2.37
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
How antimalarial drug resistance affects post-treatment prophylaxis. Malar J (2008) 1.80
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J (2011) 1.73
Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. J Infect Dis (1994) 1.53
Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (2000) 1.52
Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya. Malar J (2011) 1.42
Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Malar J (2011) 1.41
Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep (2010) 1.33
Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar J (2012) 1.28
The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Ann Trop Med Parasitol (2007) 1.21
Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. Trop Med Int Health (2008) 1.18
Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg (2008) 1.16
Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg (1992) 1.11
In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg (2005) 1.08
Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambaréné, Gabon. Am J Trop Med Hyg (2005) 1.01
Disposition of oral quinine in acute falciparum malaria. Eur J Clin Pharmacol (1991) 0.98
Artemisinin combination therapy for malaria: beyond good efficacy. Clin Infect Dis (2009) 0.92
Quinine-tetracycline for multidrug resistant falciparum malaria. Southeast Asian J Trop Med Public Health (1996) 0.84
Oral quinine for the treatment of uncomplicated malaria. BMJ (2009) 0.83
In vitro activity of chloroquine, quinine, mefloquine and halofantrine against Gabonese isolates of Plasmodium falciparum. Trop Med Int Health (2003) 0.82
[Treatment of pediatric malaria in Africa: act at issue]. Med Trop (Mars) (2006) 0.77
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg (2006) 5.91
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev (2004) 3.40
Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis (2010) 2.90
Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84
Safety and efficacy of dihydroartemisinin/piperaquine (Artekin) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg (2006) 2.79
Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis (2007) 2.66
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials (2007) 2.63
Malaria and urbanization in sub-Saharan Africa. Malar J (2005) 2.56
Four Artemisinin-Based Treatments in African Pregnant Women with Malaria. N Engl J Med (2016) 2.50
Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J (2006) 2.48
Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46
Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: an appropriate public health policy? Lancet Infect Dis (2009) 2.46
Reductions in malaria and anaemia case and death burden at hospitals following scale-up of malaria control in Zanzibar, 1999-2008. Malar J (2011) 2.45
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One (2009) 2.43
Forest malaria in Vietnam: a challenge for control. Am J Trop Med Hyg (2004) 2.34
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax. Blood (2011) 2.17
Human Plasmodium knowlesi infections in young children in central Vietnam. Malar J (2009) 2.13
Interventions to improve motivation and retention of community health workers delivering integrated community case management (iCCM): stakeholder perceptions and priorities. Am J Trop Med Hyg (2012) 2.05
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One (2009) 2.05
High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97
Spatial targeted vector control in the highlands of Burundi and its impact on malaria transmission. Malar J (2007) 1.93
Increasing malaria hospital admissions in Uganda between 1999 and 2009. BMC Med (2011) 1.92
Spatial targeted vector control is able to reduce malaria prevalence in the highlands of Burundi. Am J Trop Med Hyg (2008) 1.88
Mobile phone text messaging: tool for malaria control in Africa. PLoS Med (2012) 1.88
The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg (2004) 1.86
Failure to detect Plasmodium vivax in West and Central Africa by PCR species typing. Malar J (2008) 1.85
Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J (2009) 1.80
Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS (2007) 1.79
Malaria in central Vietnam: analysis of risk factors by multivariate analysis and classification tree models. Malar J (2008) 1.79
Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malar J (2011) 1.73
Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J Infect Dis (2008) 1.73
A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One (2010) 1.72
Vector control in a malaria epidemic occurring within a complex emergency situation in Burundi: a case study. Malar J (2007) 1.66
A significant increase in kdr in Anopheles gambiae is associated with an intensive vector control intervention in Burundi highlands. Trop Med Int Health (2008) 1.63
Research on stored biological samples: the views of Ugandans. IRB (2005) 1.59
Long-Lasting Insecticidal Hammocks for controlling forest malaria: a community-based trial in a rural area of central Vietnam. PLoS One (2009) 1.58
Malaria in pregnancy: what can the social sciences contribute? PLoS Med (2007) 1.56
Can amodiaquine be used safely during pregnancy? Lancet Infect Dis (2004) 1.55
Mitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systems. Lancet Infect Dis (2012) 1.53
Rapid decrease of malaria morbidity following the introduction of community-based monitoring in a rural area of central Vietnam. Malar J (2009) 1.51
Safety and efficacy of lumefantrine-artemether (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults. Malar J (2006) 1.50
Multilocus genotyping reveals high heterogeneity and strong local population structure of the Plasmodium vivax population in the Peruvian Amazon. Malar J (2010) 1.43
Antimalarial efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the combinations of amodiaquine + artesunate and sulfadoxine-pyrimethamine + artesunate in Huambo and Bie provinces, central Angola. Trans R Soc Trop Med Hyg (2005) 1.40
Case management of severe malaria--a forgotten practice: experiences from health facilities in Uganda. PLoS One (2011) 1.39
Intensity of malaria transmission and the spread of Plasmodium falciparum resistant malaria: a review of epidemiologic field evidence. Am J Trop Med Hyg (2007) 1.39
Commission for Africa: can it make a difference to health? Lancet (2005) 1.39
An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malar J (2012) 1.39
High complexity of Plasmodium vivax infections in symptomatic patients from a rural community in central Vietnam detected by microsatellite genotyping. Am J Trop Med Hyg (2010) 1.38
Ranking malaria risk factors to guide malaria control efforts in African highlands. PLoS One (2009) 1.38
Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J (2011) 1.38
Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg (2003) 1.38
1912-2012: a century of research on Plasmodium vivax in vitro culture. Trends Parasitol (2013) 1.37
Low perception of malaria risk among the Ra-glai ethnic minority in south-central Vietnam: implications for forest malaria control. Malar J (2010) 1.37
A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso. Malar J (2008) 1.35
Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J (2010) 1.34
Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis (2014) 1.34
Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg (2010) 1.34
Is amodiaquine failing in Rwanda? Efficacy of amodiaquine alone and combined with artesunate in children with uncomplicated malaria. Trop Med Int Health (2004) 1.33
Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events. Trop Med Int Health (2008) 1.31
Plasmodium falciparum genotyping by microsatellites as a method to distinguish between recrudescent and new infections. Am J Trop Med Hyg (2005) 1.31
Safety and efficacy of co-trimoxazole for treatment and prevention of Plasmodium falciparum malaria: a systematic review. PLoS One (2013) 1.29
The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J (2008) 1.29
Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight. Trop Med Int Health (2009) 1.28
Sero-epidemiological evaluation of changes in Plasmodium falciparum and Plasmodium vivax transmission patterns over the rainy season in Cambodia. Malar J (2012) 1.27
Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J (2008) 1.27
Plasmodium vivax sub-patent infections after radical treatment are common in Peruvian patients: results of a 1-year prospective cohort study. PLoS One (2011) 1.26
Intensity of transmission and spread of gene mutations linked to chloroquine and sulphadoxine-pyrimethamine resistance in falciparum malaria. Int J Parasitol (2003) 1.26
Malaria transmission and vector behaviour in a forested malaria focus in central Vietnam and the implications for vector control. Malar J (2010) 1.26
Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso. Trop Med Int Health (2008) 1.24
A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. PLoS One (2007) 1.22
Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria. Infect Genet Evol (2004) 1.22
Malaria burden among pregnant women living in the rural district of Boromo, Burkina Faso. Am J Trop Med Hyg (2007) 1.18
CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr (2006) 1.17
HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis (2006) 1.17
Double ethical review of North-South collaborative clinical research: hidden paternalism or real partnership? Trop Med Int Health (2011) 1.16
HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS (2010) 1.16
Efficacy of sulphadoxine-pyrimethamine alone or combined with amodiaquine or chloroquine for the treatment of uncomplicated falciparum malaria in Ugandan children. Trop Med Int Health (2004) 1.16
Traditional nets interfere with the uptake of long-lasting insecticidal nets in the Peruvian Amazon: the relevance of net preference for achieving high coverage and use. PLoS One (2013) 1.15
Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials. Stat Med (2012) 1.14
Increased risk for severe malaria in HIV-1-infected adults, Zambia. Emerg Infect Dis (2009) 1.13
Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg (2007) 1.13
True versus apparent malaria infection prevalence: the contribution of a Bayesian approach. PLoS One (2011) 1.12
Malaria in pregnancy. Mediterr J Hematol Infect Dis (2013) 1.11
Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda. Malar J (2009) 1.11
Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One (2012) 1.11
A qualitative study to assess community barriers to malaria mass drug administration trials in The Gambia. Malar J (2014) 1.11
Challenges of non-commercial multicentre North-South collaborative clinical trials. Trop Med Int Health (2012) 1.09
In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg (2005) 1.08